Deal of the Day — limited-time pharmacy picks!
Zelgor 250MG Tablet

Zelgor 250MG Tablet

Prescription requiredRx Required

Salt Composition: Abiraterone Acetate

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

120 tablet(s) in a bottle

About The Product

PROSTATE CANCER
​

Description

Zelgor 250MG Tablet is a hormonal therapy based anticancer medicine used to treat prostate cancer in men. Abiraterone acetate is the active ingredient of the medicine.

It is an anti-androgen medicine which work by blocking the production of male hormone androgen to slow down the progression of cancer. It is only meant for treating prostate cancer in men and should not be prescribed to women.

It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

Uses

  • Prostate Cancer

Side Effects

Like any other anticancer medicine, Zelgor 250MG Tablet also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:

  • Diarrhea
  • High blood pressure
  • Cough
  • Joint swelling
  • Nausea
  • Hot flashes
  • Headache
  • Increased glucose level in the blood
  • Edema (swelling)
  • Vomiting
  • Decreased potassium level in the blood
  • Fatigue
  • Anemia (low number of red blood cells)
  • Urinary tract infection

Seek medical attention in case of any unusual or severe side effects immediately.

How To Use

  • Take Zelgor 250MG Tablet in the dosage and duration exactly as prescribed by the doctor.
  • The medicine should be taken orally on an empty stomach or can be consumed one hour before or two hours after a meal.
  • In case of an overdose, contact your doctor immediately.

How It Works

  • Zelgor 250MG Tablet is an anticancer medicine prescribed to treat prostate cancer. Abiraterone acetate is the active ingredient of the medicine. I
  • t works by blocking the action of CYP17 enzyme to stop the production of male hormones that are responsible for prostate cancer. In this way, it slows down or stops the uncontrolled growth of cancer cells effectively.

Safety Advice

Alcohol
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Zelgor 250MG Tablet.
Pregnancy
Do not take Zelgor 250MG Tablet during pregnancy, as it is a highly unsafe medicine for the fetus. Also, this medicine is especially designed to treat male-related cancers.
Breast Feeding
Zelgor 250MG Tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby. Also, this medicine is especially designed to treat male-related cancers.
Driving
Zelgor 250MG Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
Consumption of Zelgor 250MG Tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
Consumption of Zelgor 250MG Tablet should be avoided without informing the doctor if you have any liver-related issues.

FAQs

Zelgor 250MG Tablet is an anticancer drug which works by managing the symptoms & slowing down or controlling the growth of cancer cells in the case of prostate cancer.

However, this medicine can't cure prostate cancer completely.

References

  • Rehman, Y., & Rosenberg, J. E. (2012). Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug design, development and therapy, 13-18. https://pubmed.ncbi.nlm.nih.gov/22291466/
  • Ryan, C. J., & Cheng, M. L. (2013). Abiraterone acetate for the treatment of prostate cancer. Expert opinion on pharmacotherapy, 14(1), 91-96. https://pubmed.ncbi.nlm.nih.gov/23199349/
  • Sonpavde, G., Attard, G., Bellmunt, J., Mason, M. D., Malavaud, B., Tombal, B., & Sternberg, C. N. (2011). The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. European urology, 60(2), 270-278. https://hero.epa.gov/reference/7353296/
  • Attard, G., Reid, A. H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., ... & de Bono, J. S. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology, 27(23), 3742-3748. https://pubmed.ncbi.nlm.nih.gov/19470933/
  • Scott, L. J. (2017). Abiraterone acetate: a review in metastatic castration-resistant prostate cancer. Drugs, 77(14), 1565-1576. https://pubmed.ncbi.nlm.nih.gov/28819727/
  • Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018). Abiraterone acetate in the treatment of prostate cancer. Biomedicine & Pharmacotherapy, 101, 211-218. https://pubmed.ncbi.nlm.nih.gov/29494958/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026